Sino Biopharm Acquires Merck’s PD-1xVEGF Bispecific Partner LaNova for up to $951M

Sino Biopharm will acquire LaNova Medicines, a Chinese cancer drug developer, in a deal valued at up to $950.9 million12345.

LaNova is known for developing PD-1xVEGF bispecific antibodies for cancer therapies and previously licensed drugs to Merck45.

The acquisition will make LaNova an indirect wholly owned subsidiary of Sino Biopharm and is expected to close within 30 business days of the announcement3.

This deal strengthens Sino Biopharm’s oncology portfolio by adding advanced cancer therapy assets focused on bispecific and multi-specific antibody approaches145.

Sources:

1. https://www.geneonline.com/sino-biopharmaceuticals-to-acquire-lanova-medicines-in-deal-worth-up-to-950-9-million/

2. https://www.geneonline.com/sino-biopharmaceutical-to-acquire-lanova-medicines-in-951-million-deal-focused-on-pd-1xvegf-cancer-therapies/

3. https://www.pharmalive.com/sino-biopharmaceutical-to-acquire-lanova-medicines-for-up-to-951-million/

4. https://www.biopharmadive.com/news/lanova-sino-biopharm-acquisition-china-cancer-drug/753051/

5. https://www.fiercebiotech.com/biotech/sino-biopharm-buys-merck-pd-1xvegf-bispecific-partner-lanova-951m